The effect of 17β-estradiol on endothelial and inflammatory markers in postmenopausal women: A randomized, controlled trial

Atherosclerosis

Volumn 165, Issue 2, 2002, Pages 301-307

  Störk, Stefan ^a,b   Von Schacky, Clemens ^a   Angerer, Peter ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

C reactive protein; Cell adhesion molecules; Estrogen; Hormone replacement therapy; Inflammation; Postmenopausal women

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ESTRADIOL; FIBRINOGEN; GESTAGEN; GESTODENE; INTERCELLULAR ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1; CELL ADHESION MOLECULE; PROGESTERONE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SMOKING; ARTERIOSCLEROSIS; BLOOD; CAROTID ARTERY DISEASE; COMPARATIVE STUDY; MIDDLE AGED;

ADULT; AGED; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CAROTID ARTERY DISEASES; CELL ADHESION MOLECULES; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE CONGENERS;

EID: 0036890084     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00242-3     Document Type: Article

References (41)

1. Barrett-Connor E., Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu. Rev. Public Health. 19:1998;55-72.
2. Grodstein F., Manson J.E., Colditz G.A., Willett W.C., Speizer F.E., Stampfer M.J. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Intern. Med. 133:2000;933-941.
3. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J. Am. Med. Assoc. 280:1998;805-813.
4. Herrington D.M., Reboussin D.M., Brosnihan K.B., Sharp P.C., Shumaker S.A., Snyder T.E., et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N. Engl. J. Med. 343:2000;522-529.
5. Nabel E.G. Coronary heart disease in women - an ounce of prevention. N. Engl. J. Med. 343:2000;572-574.
6. Manson J.E., Martin K.A. Clinical practice. Postmenopausal hormone-replacement therapy. N. Engl. J. Med. 345:2001;34-40.
7. Libby P. Changing concepts of atherogenesis. J. Intern. Med. 247:2000;349-358.
8. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:1999;115-126.
9. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342:2000;836-843.
10. Rifai N., Ridker P.M. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin. Chem. 47:2001;403-411.
11. Hwang S.J., Ballantyne C.M., Sharrett A.R., Smith L.C., Davis C.E., Gotto A.M., et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 96:1997;4219-4225.
12. Ridker P.M., Hennekens C.H., Roitman-Johnson B., Stampfer M.J., Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 351:1998;88-92.
13. Cushman M., Meilahn E.N., Psaty B.M., Kuller L.H., Dobs A.S., Tracy R.P. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler. Thromb. Vasc. Biol. 19:1999;893-899.
14. Cushman M., Legault C., Barrett-Connor E., Stefanick M.L., Kessler C., Judd H.L., et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation. 100:1999;717-722.
15. Ridker P.M., Hennekens C.H., Rifai N., Buring J.E., Manson J.E. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 100:1999;713-716.
16. de Valk-de Roo G.W., Stehouwer C.D., Meijer P., Mijatovic V., Kluft C., Kenemans P., et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler. Thromb. Vasc. Biol. 19:1999;2993-3000.
17. Walsh B.W., Paul S., Wild R.A., Dean R.A., Tracy R.P., Cox D.A., et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 85:2000;214-218.
18. Luyer M.D.P., Khosla S., Owen W.G., Miller V.M. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J. Clin. Endocrinol. Metab. 86:2001;3629-3634.
19. Herrington D.M. The HERS trial results: paradigms lost? Ann. Intern. Med. 131:1999;463-466.
20. Seljeflot I., Arnesen H., Hofstad A.E., Os I. Reduced expression of endothelial cell markers after long-term transdermal hormone replacement therapy in women with coronary artery disease. Thromb. Haemost. 83:2000;944-948.
21. Angerer P., Störk S., Kothny W., Schmitt P., von Schacky C. The effect of oral postmenopausal hormone replacement therapy on atherosclerosis in carotid arteries - a randomized, controlled trial. Arterioscler. Thromb. Vasc. Biol. 21:2001;262-268.
22. Grundy S.M., Balady G.J., Criqui M.H., Fletcher G., Greenland P., Hiratzka L.F., et al. Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee. Circulation. 95:1997;2329-2331.
23. Shen Y., Rattan V., Sultana C., Kalra V.K. Cigarette smoke condensate-induced adhesion molecule expression and transendothelial migration of monocytes. Am. J. Physiol. 270:1996;H1624-H1633.
24. Buemi M., Allegra A., Aloisi C., Corica F., Alonci A., Ruello A., et al. Cold pressor test raises serum concentrations of ICAM-1, VCAM-1, and E-selectin in normotensive and hypertensive patients. Hypertension. 30:1997;845-847.
25. Sbarouni E., Kroupis C., Kyriakides Z.S., Koniavitou K., Kremastinos D.T. Cell adhesion molecules in relation to simvastatin and hormone replacement therapy in coronary artery disease. Eur. Heart J. 21:2000;975-980.
26. van Baal W.M., Kenemans P., van der Mooren M.J., Kessel H., Emeis J.J., Stehouwer C.D. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb. Haemost. 81:1999;925-928.
27. van Baal W.M., Kenemans P., Emeis J.J., Schalkwijk C.G., Mijatovic V., van der Mooren M.J., et al. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. Fertil. Steril. 71:1999;663-670.
28. Sattar N., Perera M., Small M., Lumsden M.A. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes. Lancet. 354:1999;487-488.
29. Koh K.K., Blum A., Hathaway L., Mincemoyer R., Csako G., Waclawiw M.A., et al. Vascular effects of estrogen and vitamin E therapies in postmenopausal women. Circulation. 100:1999;1851-1857.
30. Koh K.K., Cardillo C., Bui M.N., Hathaway L., Csako G., Waclawiw M.A., et al. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation. 99:1999;354-360.
31. Blum A., Schenke W.H., Hathaway L., Mincemoyer R., Csako G., Waclawiw M.A., et al. Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women. Am. J. Cardiol. 86:2000;892-895.
32. Erikssen G., Liestol K., Bjornholt J.V., Stormorken H., Thaulow E., Erikssen J. Erythrocyte sedimentation rate: a possible marker of atherosclerosis and a strong predictor of coronary heart disease mortality. Eur. Heart J. 21:2000;1614-1620.
33. Frohlich M., Schunkert H., Hense H.W., Tropitzsch A., Hendricks P., Doring A., et al. Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women. Br. J. Haematol. 100:1998;577-581.
34. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336:1997;973-979.
35. Salomaa V., Rasi V., Pekkanen J., Vahtera E., Jauhiainen M., Vartiainen E., et al. Association of hormone replacement therapy with hemostatic and other cardiovascular risk factors. The FINRISK Hemostasis Study. Arterioscler. Thromb. Vasc. Biol. 15:1995;1549-1555.
36. Thompson S.G., Kienast J., Pyke S.D., Haverkate F., van de Loo J.C. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N. Engl. J. Med. 332:1995;635-641.
37. Meade T.W., Ruddock V., Stirling Y., Chakrabarti R., Miller G.J. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 342:1993;1076-1079.
38. van Baal W.M., Kooistra T., Stehouwer C.D. Cardiovascular disease risk and hormone replacement therapy (HRT): a review based on randomised, controlled studies in postmenopausal women. Curr. Med. Chem. 7:2000;499-517.
39. Ridker P.M., Buring J.E., Shih J., Matias M., Hennekens C.H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 98:1998;731-733.
40. Störk S., Baumann K., von Schacky C., Angerer P. The effect of 17beta-estradiol on MCP-1 serum levels in postmenopausal woman. Cardiovasc. Res. 53:2002;642-649.
41. Störk S., Störk C., Angerer P., Kothny W., Schmitt P., Wehr U., et al. Bone sialoprotein is a specific biochemical marker of bone metabolism in postmenopausal women: a randomized 1-year study. Osteoporos. Int. 11:2000;790-796.